drugset / Trial / NCT02170740

Assessment of Safety, Pharmacokinetics and the Effect of BIBR 1048 MS on Coagulation Parameters in Healthy Volunteer Subjects

NCT02170740

Phase 1 Completed 26 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

To assess safety, pharmacokinetics and the effect of BIBR 1048 MS on coagulation parameters in healthy volunteer subjects.

Timeline

Start
1999-11
Primary completion
2000-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabigatran etexilate Unknown 50 mg Oral
Subject Dabigatran etexilate Unknown 200 mg Oral
Subject Pantoprazole Other / unclassified

Indications

No indication recorded.